KR20230137293A - 인플루엔자 뉴라미니다제에 대한 광범위 중화 항체 - Google Patents

인플루엔자 뉴라미니다제에 대한 광범위 중화 항체 Download PDF

Info

Publication number
KR20230137293A
KR20230137293A KR1020237021242A KR20237021242A KR20230137293A KR 20230137293 A KR20230137293 A KR 20230137293A KR 1020237021242 A KR1020237021242 A KR 1020237021242A KR 20237021242 A KR20237021242 A KR 20237021242A KR 20230137293 A KR20230137293 A KR 20230137293A
Authority
KR
South Korea
Prior art keywords
amino acid
antibody
antigen
seq
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237021242A
Other languages
English (en)
Korean (ko)
Inventor
다비드 코르티
마테오 사무엘 피주토
안드레아 미놀라
엘리자베타 카메로니
기오르기 스넬
엘레나 페리
Original Assignee
비르 바이오테크놀로지, 인코포레이티드
후맙스 바이오메드 에스에이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 비르 바이오테크놀로지, 인코포레이티드, 후맙스 바이오메드 에스에이 filed Critical 비르 바이오테크놀로지, 인코포레이티드
Publication of KR20230137293A publication Critical patent/KR20230137293A/ko
Pending legal-status Critical Current

Links

Classifications

    • C07K16/1018—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020237021242A 2020-11-23 2021-11-19 인플루엔자 뉴라미니다제에 대한 광범위 중화 항체 Pending KR20230137293A (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063117448P 2020-11-23 2020-11-23
US63/117,448 2020-11-23
US202063123424P 2020-12-09 2020-12-09
US63/123,424 2020-12-09
US202163197160P 2021-06-04 2021-06-04
US63/197,160 2021-06-04
US202163261463P 2021-09-21 2021-09-21
US63/261,463 2021-09-21
PCT/US2021/060155 WO2022109309A1 (en) 2020-11-23 2021-11-19 Broadly neutralizing antibodies against influenza neuraminidase

Publications (1)

Publication Number Publication Date
KR20230137293A true KR20230137293A (ko) 2023-10-04

Family

ID=79021106

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237021242A Pending KR20230137293A (ko) 2020-11-23 2021-11-19 인플루엔자 뉴라미니다제에 대한 광범위 중화 항체

Country Status (13)

Country Link
US (1) US20240092876A1 (https=)
EP (1) EP4247495A1 (https=)
JP (1) JP2023551668A (https=)
KR (1) KR20230137293A (https=)
AU (1) AU2021381778A1 (https=)
CA (1) CA3199023A1 (https=)
CL (1) CL2023001462A1 (https=)
CO (1) CO2023007527A2 (https=)
IL (1) IL302963A (https=)
MX (1) MX2023005654A (https=)
PH (1) PH12023551390A1 (https=)
TW (1) TW202229329A (https=)
WO (1) WO2022109309A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025522295A (ja) * 2022-05-23 2025-07-15 ヒューマブス・バイオメッド・ソシエテ・アノニム インフルエンザノイラミニダーゼに対する広域中和抗体
AU2023358546A1 (en) * 2022-10-14 2025-05-29 Longhorn Vaccines And Diagnostics, Llc Vaccines and antibodies for the treatment and prevention of microbial infections
WO2026021428A1 (en) * 2024-07-23 2026-01-29 Westlake University Anti-neuraminidase antibodies and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7803C (https=)
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
ES2248127T3 (es) 1999-10-04 2006-03-16 Medicago Inc. Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno.
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
AU2004215125B2 (en) 2003-02-26 2011-01-06 Institute For Research In Biomedicine Monoclonal antibody production by EBV transformation of B cells
ATE492562T1 (de) 2003-09-24 2011-01-15 Kyowa Hakko Kirin Co Ltd Rekombinanter antikörper gegen humanen insulin- like growth factor
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US8119772B2 (en) 2006-09-29 2012-02-21 California Institute Of Technology MART-1 T cell receptors
US10519251B2 (en) 2013-12-30 2019-12-31 Epimab Biotherapeutics, Inc. Fabs-in-tandem immunoglobulin and uses thereof
WO2016090170A1 (en) * 2014-12-05 2016-06-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A potent anti-influenza a neuraminidase subtype n1 antibody
EP3294774B1 (en) 2015-05-13 2024-08-28 Zumutor Biologics, Inc. Afucosylated protein, cell expressing said protein and associated methods
US11254733B2 (en) * 2017-04-07 2022-02-22 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
WO2019024979A1 (en) 2017-07-31 2019-02-07 Institute For Research In Biomedicine FUNCTIONAL DOMAIN ANTIBODIES IN THE ELBOW REGION
AU2018334886B2 (en) 2017-09-22 2025-06-26 WuXi Biologics Ireland Limited Novel bispecific polypeptide complexes
CA3096703A1 (en) * 2018-05-03 2019-11-07 University Of Rochester Anti-influenza neuraminidase monoclonal antibodies and uses thereof

Also Published As

Publication number Publication date
WO2022109309A9 (en) 2022-09-01
EP4247495A1 (en) 2023-09-27
AU2021381778A9 (en) 2025-01-09
CL2023001462A1 (es) 2023-10-20
IL302963A (en) 2023-07-01
CA3199023A1 (en) 2022-05-27
US20240092876A1 (en) 2024-03-21
MX2023005654A (es) 2023-07-31
PH12023551390A1 (en) 2023-12-04
AU2021381778A1 (en) 2023-06-22
TW202229329A (zh) 2022-08-01
WO2022109309A1 (en) 2022-05-27
JP2023551668A (ja) 2023-12-12
CO2023007527A2 (es) 2023-08-18

Similar Documents

Publication Publication Date Title
JP7275405B2 (ja) Ｓａｒｓ－ｃｏｖ－２に対する抗体およびそれを使用する方法
JP2023523549A (ja) ＳＡＲＳ－ＣｏＶ－２に対する抗体およびそれを使用する方法
WO2022204202A1 (en) Antibodies that bind to multiple sarbecoviruses
KR20230137293A (ko) 인플루엔자 뉴라미니다제에 대한 광범위 중화 항체
US20240141021A1 (en) Anti-influenza antibodies and combinations thereof
JP2023550785A (ja) 複数のベータコロナウイルスに結合する抗体
TWI901812B (zh) 針對a型流感病毒的抗體
JP2025522295A (ja) インフルエンザノイラミニダーゼに対する広域中和抗体
WO2023230448A1 (en) Combination immunotherapy for influenza
WO2024006472A1 (en) Antibodies that bind to multiple sarbecoviruses
EP4562034A1 (en) Broadly neutralizing antibodies against rsv and mpv paramyxoviruses
CN116888157A (zh) 针对流感神经氨酸苷酶的广泛中和抗体
CN116997567A (zh) 抗流感抗体和其组合
EA051192B1 (ru) Антитела против вирусов гриппа а
CN116981687A (zh) 针对甲型流感病毒的抗体
WO2024118998A2 (en) Engineered anti-sars-cov-2 antibodies and methods of using the same

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000